Abstract:1134 Objectives: Liposome, as a FDA proved nano-sized drug carrier material with excellent biodegradability and biocompatibility, has been extensively used in tumor chemotherapy. Liposomes not only can encapsulate small drug molecules or signaling molecules, but also can be easily and conveniently modified externally, which is an unique advantage for developing multifunctional and theranostic nanoparticle probes. Liposomes have been radiolabeled and applied mostly for tumor detection, but very rarely for radiotherapy. Herein, 177Lu-labeled DiR-encapsulated liposome was evaluated for SPECT/Optical dual-modality imaging and biodistribution in Lewis lung cancer (LLC) xenografts. Furthermore, the therapeutic efficacy of 177Lu-labeled Dox-encapsulated liposome for combination radio-chemotherapy was firstly assessed in LLC xenografts. Methods: Biodistribution, SPECT/Optical dual-modality imaging and maximum tolerated dose (MTD) studies of 177Lu-Liposome were performed. The radiotherapy studies were begun when the tumor reached 50~80 mm3 and were compared with liposome encapsulated Doxorubicin or in combination. The liposome encapsulated Doxorubicin was given once every three days for three times totally. Tumor size and body weight were monitored every other day. When the tumor volume reached 1500 mm3 or more than 20% of the weight loss, the experiment was concluded. Results: 177Lu-Liposome are slowly cleared from the blood and at 24 h post-injection, tumor uptake reached the highest (7.55 ± 3.85%ID/g); until 72 h post-injection, the tumor is still maintaining a high uptake (5.02 ± 2.75%ID/g). The tumors were clearly visualized by the SPECT/Optical imaging. Compared with liposome encapsulated Doxorubicin alone, the 177Lu-liposome or the combination of 177Lu-liposome with doxorubicin has further notably inhibited tumor growth. From the fifth day post-treatment, the combination therapy of 177Lu-Dox-liposome has an enhanced inhibition of tumor growth than that of Dox-liposome or 177Lu-liposome, and this advantage has been maintained until the experiment was concluded. Conclusions: The 177Lu-radiolabeled payloaded liposome was prepared as a multifunctional nanoprobe. Passive targeted therapy of 177Lu-liposome is effective in LLC tumor model. 177Lu-liposome radiotherapy alone or combination with Dox-liposome, can remarkably suppress the tumor growth in LLC tumor model. Development of the multimodality imaging nanoprobe and its potential for the diagnosis and treatment is in progress.

Development Of A Novel Liposomal Nanodelivery System For Bioluminescence Imaging And Targeted Drug Delivery In Erbb2-Overexpressing Metastatic Ovarian Carcinoma

Biomimetic Metallacage Nanoparticles with Aggregation-Induced Emission for NIR-II Fluorescence Imaging-Guided Synergistic Immuno-Phototherapy of Tumors

A Novel TMTP1-modified Theranostic Nanoplatform for Targeted in Vivo NIR-II Fluorescence Imaging-guided Chemotherapy of Cervical Cancer

Targeted Bioluminescent Imaging of Pancreatic Ductal Adenocarcinoma Using Nanocarrier-Complexed EGFR-Binding Affibody–Gaussia Luciferase Fusion Protein

Assessment of therapeutic efficacy of liposomal nanoparticles mediated gene delivery by molecular imaging for cancer therapy.

Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer.

Development of a Bifunctional Immunoliposome System for Combined Drug Delivery and Imaging in Vivo.

Redox-Activated Light-Up Nanomicelle for Precise Imaging-Guided Cancer Therapy and Real-Time Pharmacokinetic Monitoring

A novel near-infrared EGFR targeting probe for metastatic lymph node imaging in preclinical mouse models

Luminescent Nanotherapeutics System for Real-Time Imaging and Membrane-Mitochondria Stepwise Targeted Drug Delivery in Ovarian Cancer

Self-evolving persistent luminescence nanoprobes for autofluorescence-free ratiometric imaging and on-demand enhanced chemodynamic therapy of pulmonary metastatic tumors

Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers

Activatable Fluorescence Imaging and Targeted Drug Delivery Via Extracellular Vesicle-Like Porous Coordination Polymer Nanoparticles.

Lu-177-labeled Payloaded Liposome for SPECT/Optical Dual-modality Imaging and Combined Radio- and Chemotherapy in LLC Mice Model

Illustration of the Behavior and the Fluorescence Recovery Process of BCPSP / DTX Nanomicelles in Vivo and the Chemical Structure of BCPSP Scheme 2 . Synthesis of Target Compound

Development of PET Radioisotope Copper-64-Labeled Theranostic Immunoliposomes for EGFR Overexpressing Cancer-Targeted Therapy and Imaging

A Vector Nanoplatform for the Bioimaging of Deep-Seated Tumors

Persistent Luminescent Nanoparticles Containing Hydrogels for Targeted, Sustained, and Autofluorescence-Free Tumor Metastasis Imaging

Bioorthogonal Surface-Edited Exosomes for Targeted Multimodal Imaging and Synergic Chemophototherapy of Oral Cancer

Engineering of exosome-liposome hybrid-based theranostic nanomedicines for NIR-II fluorescence imaging-guided and targeted NIR-II photothermal therapy of subcutaneous glioblastoma

A novel combined therapeutic strategy of Nano-EN-IR@Lip mediated photothermal therapy and stem cell inhibition for gastric cancer